Piperazine derivatives have been identified as new antidiabetic compounds. Structure-activity relationship studies in a series of 1-benzyl-4-alkyl-2-(4′,5′-dihydro-1′H-imidazol-2′-yl)piperazines resulted in the identification of 1-methyl-4-(2′,4′-dichlorobenzyl)-2-(4′,5′-dihydro-1′H-imidazol-2′-yl)piperazine, PMS 812 (S-21663), as a highly potent antidiabetic agent on a rat model of diabetes, mediated by an important increase of insulin secretion independently of R 2 adrenoceptor blockage. These studies were extended to find additional compounds in these series with improved properties. In such a way, substitution of both piperazine N atoms was first optimized by using various alkyl, branched or not, and benzyl groups. Second, some modifications of the imidazoline ring and its replacement by isosteric heterocycles were carried out, proceeding from PMS 812, to evaluate their influence on the antidiabetic activity. The importance of the distance between the imidazoline ring and the piperazine skeleton was studied third. Finally, the influence of the N-benzyl moiety was also analyzed compared to a direct N-phenyl substitution. The pharmacological evaluation was performed in vivo using glucose tolerance tests on a rat model of type II diabetes. The most active compounds were 1,4-diisopropyl-2-(4′,5′-dihydro-1′H-imidazol-2′-yl)piperazine (41a), PMS 847 (S-22068), and 1,4-diisobutyl-2-(4′,5′-dihydro-1′H-imidazol-2′-yl)piperazine (41b), PMS 889 (S-22575), which strongly improved glucose tolerance without any side event or hypoglycemic effect. More particularly, PMS 847 proved to be as potent after po (100 µmol/kg) as after ip administration and appears as a good candidate for clinical investigations.
Introduction
Non-insulin-dependent diabetes mellitus (NIDDM) is one of the most common chronic and dangerous diseases with a prevalence of 4% in the Western world's population. Despite large efforts to discover new antidiabetic drugs, only two classes of oral hypoglycemic agents (sulfonylureas and biguanides) are available for the treatment of NIDDM, and for both of them, a residual insulin secretion is necessary for activity. Sulfonylureas, such as tolbutamide and gliclazide, are hypoglycemic compounds which stimulate insulin secretion via a wellknown mechanism. 1 But a major drawback of sulfonylurea-based therapies is the occurrence of severe hypoglycemia. Biguanides (particularly metformine) act mainly by decreasing gluconeogenesis and increasing peripheral utilization of glucose. [2] [3] [4] [5] Among the most promising therapeutic approaches, imidazoline derivatives such as midaglizole, 6, 7 deriglidole, 8, 10 and efaroxan 11 were reported to be antihyperglycemic agents.
In the past few years evidence occurred that the insulin-secreting potency of imidazoline derivatives was not correlated with their R 2 antagonistic properties, 12, 13 and it has been proposed that some of these compounds could interact with imidazoline preferring binding sites (I-PBS). 14, 15 In a previous paper, 16 we described the syntheses and pharmaceutical evaluation of new antihyperglycemic 1,4-disubstituted-2-(4′,5′-dihydro-1′H-imidazol-2′-yl)-piperazines having the following general formula:
These compounds proved to be potent antihyperglycemic agents in glucose tolerance tests using a rat model of type II diabetes obtained by iv single injection of a low dose (35 mg/kg) of streptozotocin (STZ rats). The structure-activity relationships obtained within this first series showed that good potency was reached when R is a short linear or branched alkyl chain and the phenyl ring is substituted with halogens (more particularly chlorine atoms). One of the most active compounds was 1-(2′,4′-dichlorobenzyl)-4-methyl-2-(4′,5′-dihydro-1′H-imidazol-2′-yl)piperazine, PMS 812 (S-21663). Diabetic rats treated with such compounds, especially PMS 812, exhibited similar glycemia as nondiabetic control rats. 16, 17 None of the compounds of this series presented a potent affinity for adrenoreceptors and I-PBS. 16 Moreover PMS 812 was considered as a very efficient glucose-independent insulin secretagogue acting through a novel imidazoline site, linked to K + channels, and distinct from I 1 -and I 2 -PBS. 18 In the continuation of this previous work, 16 we report here the synthesis and the biological evaluation of 1,4-dialkyl-, 1,4-dibenzyl-, and 1-alkyl-4-benzyl(or phenyl)-2-(4′,5′-dihydro-1′H-imidazol-2′-yl)piperazine derivatives. Pharmacomodulation was also performed on the imidazoline moiety itself which was substituted by a methyl or replaced by isosteric groups such as oxazoline, tetrahydropyrimidine, or amidine. All these compounds were evaluated in vivo for their antidiabetic activity using glucose tolerance tests. In vitro binding experiments were performed on selected compounds and showed the same negative results as observed in the previous study. 16 
Chemistry
The 2-(4′,5′-dihydro-1′H-imidazol-2′-yl)-(41a-q, 42, and 60-63), 2-(4′,5′-dihydro-1′,3′-oxaxazol-2′-yl)-(50), and 2-(4′,5′-dihydro-1′H-imidazol-2′-yl)-(59) piperazines were prepared from the corresponding esters synthesized according to pathways described in Schemes 1-4.
Scheme 1 describes the synthesis of the major part of the 1,4-alkylated and 1,4-benzylated ester derivatives. Alkylation of ethyl piperazine-2-carboxylate (1) 16 with 2 equiv of alkyl or allyl halides in refluxing acetone or acetonitrile afforded the disubstituted compounds 2a-g. In the case of chloro or bromo derivatives, the yields of 2 were improved by addition of catalytic amounts of KI. 19 Selective alkylation in position 1 needed the use of a protective group in position 4, i.e., triphenylmethyl which was introduced by treating 1 at -10°C with 1 equiv of trityl chloride. Ethyl 4-tritylpiperazine-2-carboxylate (3) 16 was then alkylated into 5 and the trityl group removed under acidic conditions leading to 6. Reductive alkylation 20 of 6 afforded the ethyl 1-alkyl-4-methylpiperazine-2-carboxylate (7) . Monosubstitution of 1 in position 4 was performed in conditions depending on the halide derivative. Ethyl 4-alkylpiperazine-2-carboxylates 4 were achieved in refluxing acetone with alkyl halides and at room temperature with allyl and benzyl chlorides. In all cases a mixture of 4-monosubstituted and 1,4-disubstituted piperazine derivatives was obtained, but the components were easily separated by column chromatography on silica gel. No 1-Nmonosubstituted compound was detected, and this can be explained by the steric hindrance due to the substituent in position 2. This effect disappears probably by change of piperazine conformation after 4-N-alkylation.
When R is a phenyl or a dicyclopropylmethyl group and R′ a methyl or a dicyclopropylmethyl moiety, the corresponding N,N′-disubstituted ethylenediamine was prepared before cyclization into the piperazine ring as seen in Schemes 2 and 3. In Scheme 2, reductive alkylation of commercial N-benzylaminoethanol afforded 9 which was converted to chloride 10 by treatment with thionyl chloride. The amine 11, easily purified by distillation, was then obtained in good yield using an excess of ammonia (30 times more). Prolonged heating (14 days) at 80°C of 11 or ethylenediamine with dicyclopropyl ketone was required to produce the imine 13 or diimine 14. After sodium borohydride reduction (and catalytic debenzylation of compound 15), the resulting amines 16 and 17 reacted with ethyl 2,3-dibromopropionate to give 1-dicyclopropylmethyl-4-methyl (18) and 1,4-bis(dicyclopropylmethyl) (19) ester intermediates. Two isomers could be expected from the condensation of amine 17. Only the isomer 18 was isolated. The reaction is a type II NS. The first attack comes from the nonbulky nitrogen on C3 bromide of ethyl 2,3-dibromopropionate. If the methyl group is replaced by a more bulky substituent such as an isopropyl group, the cyclization provided two regioisomers, 21 suggesting that steric control plays a major role in determining the high selectivity.
N-Phenyl-substituted esters 24, 29, and 35 were prepared using the corresponding 1-phenyl-4-alkylethylenediamines 23, 28, and 34. These diamines were synthesized by three different pathways described in Scheme 3. In method A, reaction of aniline with 0.5 equiv of benzoyl chloride followed by alkylation of the resulting amide 20 with 2-chloro-1-N-methyl-N-benzylaminoethane gave compound 21. Both protecting groups were successively removed (i) by heating in acidic medium to give 22 and (ii) then by catalytic hydrogenolysis at room temperature leading to 23. If the mixture was warmed at 50°C or treated under pressure (40 psi), the phenyl group was cleaved too. The diamine 28 could not be prepared by this method, because of the cleavage of the N-isopropyl bond in strong acidic conditions, but according to method B. The N-protection of N-phenylethanolamine was selectively performed in good yield using 0.5 equiv of benzyl chloride to afford 25. This alcohol was converted into the corresponding tosylate 26 which reacted with isopropylamine to provide compound 27. Benzyl protecting group was then removed by catalytic hydrogenolysis at room temperature affording 28. Because of the sensibility to hydrogenolysis of the chloro substituent (Scheme 3, methods A and B, step d), another protocol was used (method C) for preparing diamine 34. 2-Chloroaniline was acylated by benzoyl chloride and the resulting amide 30 alkylated with chloroacetonitrile to give 31. Catalytic hydrogenation of the nitrile in the presence of Raney nickel in acetic anhydride afforded the diamide 32 which was alkylated. Acidic hydrolysis of compound 33 provided the diamine 34. Cyclization of the diamines 23, 28, and 34 with ethyl 2,3-dibromopropionate was difficult because of the low nucleophilicity of the nitrogen substituted with the aromatic ring. Anyway, the two possible regioisomers were obtained. The ratio of the esters, 24a: 24b (4:1), 29a:29b (7:3), and 35a:35b (1:9), depended on the structure of the starting diamine. Only compounds 24a, 29a, 29b, and 35b were isolated pure, the percentage of minor isomer being determined by 1 H NMR.
The preparation of ethyl piperazin-2-ylacetate (40) is described in Scheme 4. Ethyl 1,4-dibenzylpiperazine-2-carboxylate 16 was first reduced by AlLiH 4 to afford the intermediate 36. This alcohol was treated with thionyl chloride to give chloride 37 which was then substituted by CN -. Hydrolysis of the nitrile function of 38 by H 2 -SO 4 in EtOH afforded the corresponding ethyl 1,4-dibenzylpiperazin-2-ylacetate (39) . Its debenzylation led to the key intermediate 40 which could be treated as described in Scheme 1 to provide compounds 40a-c.
Imidazoline analogues were prepared according to Neef general procedure 22 with a minor modification 16 (Scheme 5). Reaction of esters with ethylenediamine in the presence of an excess of Al(CH 3 ) 3 provided the imidazoline ring (41a-q, 60-63). N-Methylethylenediamine afforded the corresponding derivative 42. The tetrahydropyrimidine 43 was prepared from 1,3-diaminopropane.
Both enantiomers of imidazoline derivative 41a were tentatively prepared from (2R)-and (2S)-(1′R, 2′S, 5′R-menthoxycarbonyl)piperazines obtained according to Aebischer et al. 23 These diastereoisomers were alkylated with isopropyl iodide and the resulting esters converted into the optically active imidazolines as described in Scheme 5. Unfortunately these enantiomers were slowly racemized in solution. 21 For this reason, no further investigation was performed on separation of enantiomers in these series (see Conclusion).
The synthetic strategy for preparing the oxazoline 50 is illustrated in Scheme 6. Compound 46 was prepared first by N-benzylation of ethanolamine, then protection Intermediates 24a,b, 29a,b, and 35a,b a a (a) 0.5 equiv of Ph-COCl, CH2Cl2; (b) (1) NaH, DMF, 60°C, (2) Bzl-N(Me)CH2-CH2-Cl; (c) 6 N HCl, EtOH/H2O; (d) H2, Pd/C, EtOH; (e) Br-CH2CHBr-CO2-Et; (f) 0.5 equiv of Bzl-Cl, rt, C6H6; (g) Ts-Cl, NEt3, CHCl3, 0°C; (h) Me2CHNH2, CH2Cl2; (i) (1) NaH, DMF, rt, (2) Cl-CH2-CN; (j) Raney Ni, (MeCO)2O, H2 40 psi; (k) (1) NaH, DMF, rt, (2) MeI. *Isolated and purified for further syntheses.
of the alcohol 44 using dihydropyran, and finally removal of both benzyl protecting groups of the substituted ethanolamine 45. Condensation of the amine 46 with ester 7c in the presence of Al(CH 3 ) 3 afforded the amide 47. After removal of the THP protecting group, the resulting alcohol 48 was converted into the corresponding chloride 49. Its cyclization in the presence of NaOH gave the oxazoline analogue 50.
The synthesis of the amidines 52a, 52b, and 56 (Scheme 7) started from the cyanopiperazines 51 or 55 prepared by cyclization of N,N′-disubstituted ethylenediamine and 2,3-dibromopropionitrile in refluxing benzene. According to Garigipati's method, 24 the amidines 52a, 52b and 56 were obtained from nitriles by addition of methylchloroaluminum amides 25 generated from trimethylaluminum and ammonium chloride or methylamine hydrochloride.
The first step of the imidazole analogue 59 synthesis (Scheme 8) was the reduction of ethyl 1-(2′,4′-dichlorobenzyl)-4-methylpiperazine-2-carboxylate into the alcohol 57. 16 Subsequent oxidation into aldehyde 58 under Swern's conditions 26 and then reaction with ammonia and glyoxal 27 gave the final product. Significance and Validity of Pharmacological Parameters. As previously described, 16 antidiabetic properties of all the synthesized compounds were evaluated in vivo by their ability to improve the glucose tolerance during intravenous glucose tests (IVGTT) performed on a rat model of mild diabetes. 28 This model presents moderate basal hyperglycemia, glucose intolerance, and impairment of the glucose-induced insulin secretion which are the main features in patients with NIDDM. IVGTT were carried out after a single ip administration of 100 µmol/kg of each synthesized molecule, and glucose tolerance was evaluated according to three parameters: (i) G 30 , which is the glycemic value at 30 min after glucose administration, (ii) ∆G, which represents the increase of glycemia over the baseline integrated over a period of 30 min following the glucose load, and (iii) K, which is the rate of glucose disappearance between 5 and 30 min after glucose administration.
To correct for the slight variations that appeared when glucose tolerance tests were performed with different control diabetic rats, we expressed the results as a percentage (∆G*) of variation of ∆G between treated and untreated diabetic rats:
In the same way, we defined G 30 * and K*. To be considered as effective antidiabetics, compounds must induce high percentages of variation for ∆G*, K*, and G 30 *. Results around 100% or more indicate that the parameters for the treated diabetic animals are close to those obtained with nondiabetic control animals. Among these three parameters, G 30 which is obtained via a direct measurement, is considered as the most relevant when the compounds are tested po.
Results and Discussion
Within this new series, the first synthesized and evaluated compounds were symmetrically substituted on both piperazine nitrogen atoms by branched alkyl or cycloalkyl chains.
The compounds 41a, 41b, and 41f, respectively substituted by two isopropyl, isobutyl, or 2-methylbutyl groups, show potent effects on glycemia with values similar to those of nondiabetic control rats. As in our first paper, 16 this correlates very well with their effects on ∆G* and G 30 * with values around 100% (Table 1) . Their effect on the K parameter is also very significant but less potent, since K* values remain between 47% for compound 41a and 82% for compound 41f. The derivatives 41c and 41g, substituted by two cyclopentyl and neopentyl groups, are clearly less active on ∆G (∆G * ) 58% and 54%, respectively) than their isobutyl (compound 41b, ∆G * ) 141%) and 2-methylbutyl (compound 41f, ∆G* ) 104%) analogues, probably due to problems of steric hindrance. Concerning the compound 41c, there is a slight discrepancy between the effects on ∆G and K which is rather moderate and the effect on G 30 which is very high (G 30 * ) 103%). Compound 41h, substituted by two dicyclopropylmethyl groups, was slightly less active on ∆G (∆G* ) 24%). This is not surprising if cyclopropyl molecular orbitals are considered to have a partial π character so that compound 41h is comparable in some respects with the dibenzyl-substituted imidazolinylpiperazines which were found inactive in our first paper. 16 Replacement of the two isobutyl moieties (compound 41b) by two 2-methyl-2-propenyl substituents (compound 41e) has no deleterious effect on the three parameters which are all around 100%. This is not the case for the diallylsubstituted compound 41d which is almost inactive
Unsymmetrically substituted compounds (Table 1) were then prepared and evaluated. The compounds 41l and 41m, 4-methyl and respectively 1-isobutyl and 1-dicyclopropylmethyl substituted, are equipotent with values around 100% for ∆G* and around 50% for G 30 * and K*. It is noteworthy that compound 41m is much more potent than its inactive symmetrically substituted analogue 41h, while compound 41l is only slightly less active than its analogue 41b but much more potent than compound 41k (∆G* ) 40%, G 30 * ) 21%, K* ) 42%), for which the methyl and isobutyl substituents have been inverted. Surprisingly, while compound 41i, 1-isobutyl, 4-allyl remains very potent (∆G* ) 115%), its 4-propenyl analogue 41j is clearly less active (∆G* ) 53%). When compared to symmetrically substituted compounds 41d and 41e, the results are inverted. Compounds bearing a phenyl or a 2-chlorophenyl group were finally synthesized and evaluated (compounds 41n, 41o, 41p, 41q). All of them proved to be inactive on ∆G so that a phenyl substitution seems to be unfavorable. An expected pK a variation cannot be taken into account. In our first paper, 16 we clearly demonstrated that the protonation center at physiological pH in such series was the imidazoline ring (pK a ∼ 9.5) and not the piperazine one (pK a ∼ 5.5). Consequently this negative effect should be due to a decrease of flexibility of these molecules. Moreover, concerning compound 41o, significant unexplainable discrepancies can be noticed concerning the effects on ∆G and those on K and G 30 . It is noteworthy that the 2-chlorobenzyl analogue of compound 41p, PMS 774, is very potent (∆G* ) 81%, K* ) 98%, G 30 * ) 103%). 16 In a second step, chemical modulations on the imidazoline pharmacophore itself were performed ( Table  2) . Insertion of a methylene spacer between the piperazine and imidazoline rings results in a very clear ∆G* ) | ∆G treated STZ rats -∆G untreated STZ rats ∆G untreated STZ rats -∆G control rats decrease of hypoglycemic properties for three of the four synthesized derivatives (60, 62, and 63). Concerning the fourth compound, the dibenzyl derivative 61, a moderate but clear effect on ∆G* is observed, while its analogue without the methylene spacer was totally inactive. 16 It can be postulated that introduction of a spacer gives more flexibility to this bulky molecule and consequently allows a better access to a hypothetic imidazoline binding site. Substitution of the imidazoline ring by a methyl in position 1 (compound 42) leads to a poorly active compound (∆G* ) 24%) as compared to its very potent nonmethylated analogue PMS 812 (S-21663) (∆G*) 105%). Replacement of the imidazoline by an imidazole (compound 59) or an oxazoline (compound 50) induces a total loss of activity. However only a partial decrease in activity is observed for the tetrahydropyrimidine analogue 43 (∆G* ) 47%) as compared to PMS 812 (∆G* ) 105%). The results obtained with amidine and N-methylamidine are more contrasted. The Nmethylamidino diisopropyl compound 56 is clearly less potent (∆G* ) 43%) than its imidazoline counterpart 41a (∆G* ) 138%), and the amidino 52a (∆G* ) 55%) and N-methylamidino 52b (∆G* ) 50%) dibenzyl derivatives are moderately active, while their imidazoline analogue is totally inactive. 16 Table 1 . Variation of the Glycemia Parameters after ip Administration of 100 µmol/kg of 1,4-Disubstituted-2-(4′,5′-dihydro-1′H-imidazol-2′-yl)piperazines to STZ Rats a a Three-month-old male Wistar rats (250 g) treated with 35 mg/ kg iv of streptozotocin. b ∆G, incremental glycemia values over baseline integrated over 30 min after glucose (0.5 g/kg iv) administration. c G30, glycemia value 30 min after glucose administration. d K, rate of glucose disappearance between 5 and 30 min after glucose administration.All results (asterisk) are expressed as the percent of variation of the parameters between treated rats (with an ip administration of 100 µmol/kg of the tested compound) and untreated rats. Number of treated rats for each compound included between 4 and 8 ((SEM). Due to their good activity via ip administration, compounds 41a, 41b, 41e, 41f, and 41i were selected to be tested via po administration at 100 µmol/kg (Table  3) . Among these five derivatives, only compounds 41a and 41b proved to be active via po administration with significant effects on G 30 * (respectively 73% and 66%). This could be explained by the poor bioavailability of the other compounds with (i) perhaps problems of metabolism for the unsaturated compounds 41e and 41i, despite their isolipophilicity (log P ) 1.45 and 1.30, respectively) with the congener 41a, or (ii) a too high hydrophobicity for compound 41f (log P ) 3.22) as compared to 1.15 and 2.18 for compounds 41a and 41b, respectively (cf. Table 3 and Experimental Section for calculations). It seems that the range of lipophilicity required for a good bioavailability of these compounds is included between 2.2 and 1.1 units of log P approximately. Moreover, the log P value of PMS 812, a very potent in vivo antihyperglycemic compound, 16, 17 was equal to 2.21.
Compound 41a was then selected for further pharmacological studies and first evaluated for its capacity to stimulate the secretion of insulin during IVGTT. Surprisingly and unlike the substituted benzylpiperazine derivative PMS 812, [16] [17] [18] compound 41a, PMS 847 (S-22068), has a poor stimulating effect on insulin secretion. 30 The in vitro binding experiments performed with these compounds demonstrated that they were clearly devoid of any affinity for the I 1 and I 2 binding sites as well as for the R 2 adrenoreceptor (K I g 10 -5 M). This is in agreement with an increasing number of studies showing that R 2 adrenergic antagonists are able to stimulate insulin secretion independently of R 2 and I 1 , I 2 blockage. 16, 17, 28, 29, [31] [32] [33] [34] [35] [36] [37] [38] 
Conclusion
In conclusion, 29 new imidazoline derivatives were synthesized and evaluated (100 µmol/kg via ip administration) for their antidiabetic properties in glucose tolerance tests. Seven of them (compounds 41a, 41b, 41e, 41f, 41i, 41l, and 41m) have a potent effect on the glucose tolerance via ip administration, and 2 of them (compounds 41a and 41b) were also found active after po administration (100 µmol/kg). Surprisingly, compound 41a (PMS 847, S-22068) 30 has no effect on insulin secretion and is devoid of any affinity either for the I 1 and I 2 imidazoline binding sites or for the R 2 adrenoreceptors. This compound undergoes current complementary studies in order to investigate its possible mechanism of action. Concurrently, the structureactivity relationships that have been established with this present work and the previous one 16 show unambiguously that an unsubstituted imidazoline ring is a required pharmacophore for potent antihyperglycemic properties. All attempts to substitute it or to replace it by imidazole, tetrahydropyrimidine, oxazoline, or amidine result in a clear decrease or a total loss of activity. This could be an argument for the involvement of specific and still unknown imidazoline binding sites in the regulation of glucose homeostasis.
Finally it is noteworthy that a spontaneous slow racemization at the chiral carbon 2 is observed in such molecules (cf. compound 41a, see Chemistry). This is a consequence of a hydrogen transfer to the imidazoline ring inducing an intermediate tautomeric form. It is reasonable to suspect that such a phenomenon takes place in vivo. If their exceptional conformational flexibility is taken into account, 16 such derivatives should present great adaptability to special binding sites and probably interact via dynamic processes. 39 
Experimental Section
Chemistry. General Methods. The purity of each compound was checked by thin-layer chromatography on TLC plastic sheets (silica gel 60F254, layer thickness 0.2 mm) from Merck. Column chromatography purification was carried out on silica gel 60 (particle size 0.063-0.200 mm) from Merck, without any special treatment. All melting points were determined in a digital melting point apparatus (Electrothermal) and are uncorrected. The structures of all compounds were confirmed by IR and 1 H NMR spectra. IR spectra were obtained with an ATI Mattson Genesis Series FTIR infrared spectrometer, and 1 H NMR spectra were recorded in CDCl3 on a Brucker AC 200 spectrometer or a JEOL PMX60SI NMR spectrometer using hexamethyldisiloxane (HMDS) as an internal standard. All elemental analyses were within (0.4% of theoretical values.
Preparation of Alkyl and Benzyl Ester Intermediates 2a-g, 7a-d, and 8a-c (Scheme 1). Ethyl 1,4-Diisopropylpiperazine-2-carboxylate Dihydrochloride (2a).
A suspension of 1‚2HCl (23.1 g, 0.1 mol) and dry K 2CO3 (40 g ) in 200 mL of acetonitrile was stirred for 1 h at room temperature to regenerate the free amine; 51 g (0.3 mol) of isopropyl iodide was added, and the mixture refluxed for 24 h. The reaction mixture was cooled and filtered and the filtrate diluted with ether. The organic layer was washed with water and dried over MgSO 4, and the solvents were removed in vacuo. The crude product was dissolved in CH2Cl2, and after the product was cooled in an ice bath, EtOH saturated with HCl gas was added until acidic pH. The solvents were evaporated and the dihydrochloride salt recrystallized from CH 2Cl2-acetone-ether to afford 22 g (72%) of 2a‚2HCl: mp 94-95°C. Usual treatment of this salt gave free amine 2a as a colorless oil: IR (film, cm -1 ) ν 1755 (CdO); 1 H NMR δ 4.16 Compounds 4b and 4c were prepared by the same procedure using the corresponding bromo derivative.
Ethyl 1-Isobutyl-4-(triphenylmethyl)piperazine-2-carboxylate (5a). A mixture of 3 16 (40 g, 0.1 mol), dry K2CO3 (40 g), KI (4 g), and isobutyl bromide (16.4 g, 0.12 mol) in acetonitrile (400 mL) was heated at 80°C with stirring for 15 h. After filtration of solid material, the filtrate was diluted with ether and washed with water. The aqueous layer was extracted with ether, and the combined organic layers were dried over MgSO 4. Solvents were removed in vacuo, and this crude 5a was used in the next step without purification.
Compounds 5b-d were prepared using the corresponding chloro derivatives.
Ethyl 1-Isobutylpiperazine-2-carboxylate (6a). Crude 5a was dissolved in acetone (600 mL) containing 12 M HCl (25 mL). After 3 h stirring at room temperature, the solvent was removed in vacuo and the residue was partitioned between ether and water. The aqueous layer was treated with a saturated NaHCO3 solution until basic pH and extracted with ether. The organic phase was dried over MgSO4 and the solvent evaporated under vacuo. The crude product was purified by column chromatography using first petroleum ether/ether (30:70, v/v) Compounds 6b-d were prepared using the same procedure. Ethyl 1-Isobutyl-4-methylpiperazine-2-carboxylate (7a). A mixture of 6a (17 g, 0.08 mol), 37% formaldehyde (10 mL, 0.13 mol), and formic acid (10 mL, 0.25 mol) in MeOH (110 mL) was refluxed for 20 h. After evaporation of the solvent, the residue was taken up in ether and washed with saturated NaHCO3 solution until basic pH. The organic layer was washed with water and dried over MgSO4, and the solvent was removed in vacuo. The crude product was purified by crystallization of the hydrochloride salt from ethanol-ether. Usual treatment of this salt afforded 15. 3H, s, H3C-N) .
2-Chloro-N-benzyl-N-methylethylamine
N-Benzyl-N-methylethylenediamine (11). 10 (110 g, 0.5 mol) was solubilized in a 28% aqueous ammonia solution (1 L) and stirred for 3 days at room temperature. The water was partially removed in vacuo, and 28 g of KOH pellets was added. The aqueous layer was extracted with CH2Cl2, and the organic layer was dried over MgSO4 and concentrated. The crude product was purified by distillation (E15 ) 152-154°C) to give 49 g (60%) of 11: IR (film, cm 05 mol) of dicyclopropyl ketone in benzene (50 mL) was refluxed for 15 days using a Dean-Stark apparatus. Advancement of the reaction was followed by IR. The solvent was evaporated, and the residue was diluted in dry and cold MeOH (50 mL); then 1.9 g (0.05 mol) of NaBH 4 was added portionwise. After 15 h stirring at room temperature, the mixture was poured into water containing 2 g of NaOH, saturated with NaCl, and extracted with hexane. The organic layer was dried over MgSO 4 07 mol) and triethylamine (24 mL, 0.17 mol) in toluene (100 mL) was added dropwise, but rapidly, ethyl 2,3-dibromopropionate (18.3 g, 0.071 mol) in toluene (100 mL). After the addition, the reaction mixture was stirred at 80°C for 3 h, then cooled, and filtered. The filtrate was washed with saturated aqueous NaHCO 3 (100 mL). The organic layer was dried over MgSO4 and the solvent removed in vacuo. The crude product was purified by column chromatography using petroleum ether/ether (80:20, v/v) as eluent to afford 9.5 g (54%) of 18 as a pale-yellow oil: IR (film, cm -1 ) ν 3100, 3080 (cyclopropyl), 1745 (CdO); 1 20H, 2m, H cyclopropyl) . 24a, 29a,b, and 35b (Scheme 3). N-Benzoylaniline (20) . To a cold solution of 150 mL (1.65 mol) of aniline in CH2Cl2 (400 mL) was added dropwise 90 mL (0.776 mol) of benzoyl chloride in CH2Cl2 (200 mL). After 2 h stirring at room temperature, water (300 mL) and concentrated HCl (20 mL at 37%) were added. The mixture was filtered and the solid product washed with water and then with acetone to afford 120 g of 20. The filtrate was concentrated to provide another 28 g of 20 (global yield 97%): mp 162-164°C; IR (film, cm -1 ) ν 3399 (NH), 1642 (CdO); 1 H NMR δ 7.82 (1H, br s, D2O exchange, H-N), 7.80-7.04 (10H, m, Ar-H).
Preparation of 1-Phenyl-4-alkyl Ester Intermediates
N-Benzoyl-N-phenyl-N′-benzyl-N′-methylethylenediamine (21). To a stirred cold suspension of NaH (25 g, 0.625 mol) in DMF (100 mL) was added dropwise the amide 20 (118 g, 0.6 mol) in DMF (500 mL). The mixture was stirred for 1 h at room temperature, and then 105 g (0.57 mol) of 2-chloro-N-benzyl-N-methylethylamine dissolved in DMF (100 mL) was added. The solution was stirred and heated for 3 h at 60°C, and after the solution had cooled in an ice bath, water (500 mL) was added. The aqueous layer was extracted several times with ether and the etheral layer washed with aqueous HCl until acidic pH. The aqueous layer was extracted with CH2-Cl2 (the hydrochloride salt of compound 21 is very soluble in CH2Cl2) and the organic layer washed with aqueous Na2CO3 until basic pH. The dichloromethane phase was dried over MgSO4 and concentrated. The crude product was crystallized from pentane/ether (90:10, v/v) to give 120 g (58%) of 21 as a white powder: mp 52.5-53°C; IR (KBr, cm -1 ) ν 1634 (CdO), 1594 (CdC); Ethyl 1-Phenyl-4-methylpiperazine-2-carboxylate (24a). The title compound was prepared according to the procedure used for 18, starting from 65 g (0.29 mol) of 23 dihydrochloride salt (the free base was regenerated in situ). The crude product was purified by column chromatography using petroleum ether/ether (first 80:20 then 70:30, v/v) as eluent, to afford 27 g (39%) of the two isomers 24a and 24b. The pure isomer 24a was obtained by crystallization of the dihydrochloride salt from acetone-ether and then recrystallized from acetone/ethanol (90:10, v/v): mp 159°C. The mother liquor was concentrated, and the residue, after alkalization, gave a pale-yellow oil, mixture of the two isomers 24a and 24b in the ratio 1:1; IR (free base, film, cm -1 ) of 24a: ν 1743 (CdO), 1599 (CdC); 1 H NMR δ 7.18-7.10, 6.77-6.67 (5H, 2m, Ar-H), 4.36 (1H, t, J ) 3.3 Hz, H-N)*, 4.00 (2H, dq, J ) 6.5 and 1.8 Hz, H2C-O), 3.46-2.04 (6H, 3m, three H2C-N), 2.20 (3H, s, H3C-N), 1.05 (3H, t, J ) 6.5 Hz, H3C-CH2O). *This signal allowed to determine the ratio of the isomers. It presents 0.5H in the mixture obtained from the mother liquor. N-Benzyl-N-phenyl-2-(p-tolylsulfonyloxy)ethylamine (26). 25 (113.5 g, 0.5 mol) was dissolved in chloroform (500 mL) and cooled in a salted ice bath. Et3N (83 mL, 0.6 mol) was then added, followed by the addition of 95.2 g (0.5 mol) of p-toluenesulfonyl chloride in one portion with constant stirring. The reaction was complete in 24 h at 0°C. Ether (200 mL) was added, and the precipitate of triethylamine hydrochloride was filtered. The filtrate was concentrated in vacuo and the residue dissolved in ether. The etheral phase was washed successively with diluted HCl and water. The organic layer was dried over MgSO4, and the solvent was removed under reduced pressure. The crude tosylate was purified by crystallization from hexane/CH2Cl2 to give 26 (127 g, 67%) as white crystals: mp 82-84°C; IR (KBr, cm -1 ) ν 1598 (CdC); 1 1 H NMR δ 7.23-7.14, 6.86-6.75 (5H, 2m, Ar-H), 4.15 (2H, q, J ) 7.1 Hz, H2C-O 
N-Benzyl-2-anilinoethanol (25)
. To 175.5 g (1.28 mol) of 2-anilinoethanol in benzene (200 mL) was added 79 g (0.
N-(o-Chlorophenyl)-N-benzoyl-N′-acetyl-N′-methylethylenediamine (33).
To a cooled (0°C) suspension of NaH (3.6 g, 0.09 mol) in DMF (50 mL) was added dropwise the diamide 32 (25.9 g, 0.082 mol) in DMF (100 mL). The mixture was then stirred for 3 h at room temperature, and 13 g (0.09 mole) of methyl iodide dissolved in DMF (30 mL) was added dropwise. The solution was stirred overnight, then poured into cold water (500 mL), and extracted with CH 2Cl2. The organic layer was dried over MgSO4, and the solvents were evaporated in vacuo to dryness. The crude product 33 was used in the next step without purification.
N-(o-Chlorophenyl)-N′-methylethylenediamine Dihydrochloride (34). This compound was prepared using the procedure described to prepare compound 22 except the time of the reaction (48 h). The hydrochloride salt was crystallized from acetone/ethanol (90:10, v/v) to afford 10 g (47% for the two steps) of 34: mp 116°C; IR (KBr, cm 
mixture of the two isomers 35a and 35b in a 1:1 ratio. The 1 H NMR spectrum of 35b was similar to that of 29b, particular signal δ 2.35 (3H, s, H3C-N) .
Preparation of the Ester Intermediates 39 and 40a-c (Scheme 4). 1,4-Dibenzyl-2-(hydroxymethyl)piperazine (36).
A stirred suspension of LiAlH 4 (5 g, 0.13 mol) in dry tetrahydrofuran (200 mL) was cooled at 0°C, and 57 g (0.17 mol) of ethyl 1,4-dibenzylpiperazine-2-carboxylate in tetrahydrofuran (200 mL) was added. The mixture was stirred for 20 h at room temperature, then cooled, and treated carefully with aqueous NaOH (20%). The aqueous layer was extracted with CH 2Cl2, and the extracts were dried over MgSO4. After the solvents were removed, crystallization of the crude product afforded 47 g (93%) of 36 as a white powder: mp 70-72°C; IR (KBr, cm -1 ) ν 3400 (OH), 1600 (CdC); 1 6H, 3m, H2C-N) .
1,4-Dibenzyl-2-(chloromethyl)piperazine (37). Compound 37 was prepared according to the procedure used to dispose 10. The crude product obtained from 20 g (0.068 mol) of 36 was partitioned between ether and water. The aqueous layer was treated with Na 2CO3 and extracted with CHCl3. The organic layer was dried over MgSO4 and the solvent removed in vacuo. The residue was purified by column chromatography using petroleum ether/ether (90:10, v/v) as eluent, to afford 17 g (79%) of 37 as a yellow oil: IR (film, cm -1 ) ν 1600 (CdC); 
1,4-Dibenzyl-2-(cyanomethyl)piperazine (38).
To a refluxing solution of KCN (4.57 g, 0.07 mol) in water (20 mL) was added dropwise the halide 37 (17 g, 0.054 mol) in ethanol (20 mL). The mixture was stirred and refluxed for 3 h. Ethanol was evaporated, the residue was taken up in chloroform, washed with water, and dried over MgSO 4, and the solvent was removed in vacuo. Crystallization from hexane/ether gave 13.2 g (80%) of 38 as a white powder: mp 80-89°C; IR (film, cm -1 ) ν 2215 (CN), 1600 (CdC); 1 H NMR δ 7.21 (10H, br s, Ar-H), 3.72 and 3.40 (2H, AB spectrum, J ) 13.5 Hz, H2C-Ar), 3.45 (2H, s, H2C-Ar), 3.00-2.10 (9H, m, H piperazine and H2C-CN).
Ethyl 1,4-Dibenzylpiperazin-2-ylacetate (39). A mixture of 13.2 g (0.043 mol) of 38, H2SO4 (10 mL at 95%), and ethanol (30 mL) was stirred and refluxed for 3 h. Then ethanol was evaporated, and the residue was taken up in chloroform, washed with water, and dried over MgSO4. Evaporation of the organic layer gave a crude product which was purified by column chromatography using petroleum ether/ether (90:10, v/v) as eluent to give 11.4 g (75%) of 38 as a yellow oil: IR (film, cm -1 ) ν 1720 (CdO), 1600 (CdC); 1 H NMR δ 7.23-7.14 (10H, m, Ar-H), 4.07 (2H, dq, J ) 6.95 and 3.25 Hz, H2C-O), 3.72 and 3.34 (2H, AB spectrum, J ) 13.3 Hz, H2C-Ar), 3.47 and 3.38 (2H, AB spectrum, J ) 13.1 Hz, H2C-Ar), 3.07-3.02 (1H, m, HC-N), 2.60 and 2.22 (8H, m, three H2C-N and H2C-CdO), 1.15 (3H, t, J ) 7.10 Hz, H3C-CH2O).
Ethyl Piperazin-2-ylacetate Dihydrochloride (40). To a solution of 39 (20 g, 0.057 mol) in ethanol (200 mL) were added concentrated HCl (9 mL) and 10% palladium on charcoal. The mixture was kept under H2 atmosphere for 5 h at 50°C. The catalyst was filtered and the solvent removed in vacuo. The crude product 40 was used in the next step without purification.
Ethyl 1,4-diisopropylpiperazin-2-ylacetate (40a): prepared like 2a starting from 40; 1 H NMR δ 4.07 (2H, q, J ) 7. 13 Hz , H2C-O), 3.16-2.28 (11H, m, H piperazine, H2C-CO2,  two HC(CH3)2), 1.22-0.90 (15H, m, H3C-CH2O, two (H3C)2-CH, H3C signals overlapping) . Ethyl 1-(2′,4′-dichlorobenzyl)-4-methylpiperazin-2-ylacetate (40b) and ethyl 1-(2′-methoxybenzyl)-4- The compounds 41a-q, 42, and 60-63 were prepared as described in our previous publication 16 using the corresponding esters. All the 1 H NMR spectra were recorded from the free bases. The hydrogens of the imidazoline ring of compounds  41a, 41b, 41d, 41e, 41g, 41n, 41j, 41l, and 41m gave unresolved peaks. The corresponding signal is very broad, and the summit of this signal was a coalescence point. Preparation of Amidine Analogues 52a, 52b, and 56 (Scheme 7). 1,4-Dibenzyl-2-cyanopiperazine Dihydrochloride (51). To a hot (80°C) stirred solution of N,N′-dibenzylethylenediamine (72 g, 0.3 mol) and triethylamine (100 mL, 0.72 mol) in toluene (300 mL) was added dropwise, but rapidly, freshly distilled 2,3-dibromopropionitrile (70 g, 0.3 mol) in toluene (300 mL). After the addition, the reaction mixture was stirred at 80°C for 3 h, then cooled, and filtered. The filtrate was washed with saturated aqueous NaHCO 3 (200 mL). The organic layer was dried over MgSO4 and the solvent removed in vacuo. The crude product was dissolved in anhydrous EtOH (400 mL) and saturated with HCl gas. The addition of ether gave a precipitate of 51 (65. procedure. 25 The mixture was stirred 1 h at room temperature; then 10 g (0.034 mol) of 51 dissolved in toluene (50 mL) was added dropwise. The solution was heated at 80-90°C overnight. After cooling in an ice bath, MeOH/H2O (80:20, v/v) was added carefully and the mixture filtered. The salts were washed with CHCl3, and the filtrate was acidified. The solvents were evaporated to dryness; the residue was taken up in CHCl3 and filtered again. After evaporation of CHCl3, the crude product was purified by column chromatography using CHCl3/ MeOH (95: 5, v/v) as eluent to give 4.2 g (36%) of 52a as a white powder: mp 175-177°C (CH2Cl2/ether); IR (film, cm 1-(2′,4′-Dichlorobenzyl)-4-methyl-2-formylpiperazine (58). To a solution of DMSO (20 mL) in dry CH2Cl2 (140 mL) was added dropwise for 10 min at -60°C freshly distilled oxalyl chloride (30 mL) in dry CH2Cl2 (60 mL) with stirring under nitrogen atmosphere. After 15 min, 15 g of 57 in dry CH2Cl2 (250 mL) was added dropwise to the solution mixture while the temperature was maintained at -60°C. After stirring 90 min, triethylamine (56 mL) was added quickly and the reaction mixture was allowed to warm to -30°C. After stirring for 2 h, the solution mixture was allowed to warm to room temperature and concentrated. The residue was taken up in chloroform; the organic layer was washed with water and dried over MgSO4. After evaporation the residue was purified by column chromatography using ether as eluent to afford 58 as a viscous oil (6.76 Pharmacology. Animals and Treatments. Three monthold male Wistar rats (Iffa-Credo, France) weighing about 250 g were used in all the experiments. The animals were housed in wire-bottomed cages and maintained at 21 ( 2°C in a room with a 12-h fixed light-dark schedule. Water and standard laboratory chow (UAR, Villemoison-sur-Orge, France) were freely available.
Moderate diabetes were obtained by a single iv injection of a low dose (35 mg/kg) of streptozotocin (STZ) dissolved in a citrate buffer 28 under ketamine hydrochloride anesthesia (75 mg/kg ip; Imalgene, Mérieux, France). These rats were called STZ rats. Control rats received an injection of the vehicle under the same conditions.
Glucose homeostasis and insulin secretion were assessed by glucose tolerance tests performed 2 weeks after STZ injection.
Intravenous Glucose Tolerance Tests (IVGTT). Glucose was dissolved in 0.9% saline and given by the saphenous vein route (0.5 g/kg) in rats under pentobarbital anesthesia (60 mg/ kg ip; Clin-Midy, France). Blood samples were collected sequentially from the tail vessels before and 5, 10, 15, 20, and 30 min after the injection of glucose. They were then centrifuged, and the plasma was separated. Plasma glucose concentration was immediately determined in a 10-µL aliquot, and the plasma left was kept at -20°C until radioimmunoassay of insulin.
Drug Administration and Antidiabetic Activity. The 2-(4′,5′-dihydro-1′H-imidazol-2′-yl)piperazine derivatives were tested by a single ip injection of 100 µmol/kg in the STZ rat 20 min before the IVGTT. All the compounds were used in the form of hydrochloride salts and were water-soluble. Antidiabetic activity of the compounds was evaluated using two parameters: ∆G, which represents the increase in glycemia over baseline integrated over a period of 30 min (IVGTT) following the glucose load, and K, which is the rate of glucose disappearance between 5 and 30 min (in the case of IVGTT), after glucose administration. The K coefficient was calculated only during IVGTT.
Tissue and Membrane Preparation. Cerebral cortex was obtained from whole bovine brains and homogenized in 20 volumes of ice-cold 50 mM Tris-HCl buffer (pH 7.4). The homogenate was centrifuged twice at 48000g for 25 min at 4°C
. The pellet (used for R 2 binding assays) was resuspended in a phosphate buffer (pH 7.4), flash-frozen, and stored at -80°C until R2 binding assays. Reticular nucleus from calf's bulbis was homogenized in icecold 50 mM Tris-HCl buffer (pH 7.7) containing 5 mM EDTA.
The homogenate was centrifuged at 500g for 10 min at 4°C. The pellet (P1) was resuspended in the same buffer and centrifuged again. The combined supernatants were centrifuged at 50000g for 25 min at 4°C. The resulting pellet (P2) was resuspended in 50 mM Tris-HCl buffer (pH 7.7) containing 0.1 mM p-methanesulfonyl fluoride, incubated for 30 min at 25°C, then centrifuged again in the same conditions, resuspended in 50 mM Tris-HCl (pH 7.7), flash-frozen, and stored at -80°C until I1-imidazoline binding assays.
Renal cortex was obtained from male New Zealand white rabbits and homogenized in ice-cold preparation buffer (20 mM NaHCO3). 42 The homogenate was centrifuged at 40000g for 30 min at 4°C. The pellet was resuspended in 50 mM TrisHCl buffer containing 0.5 mM EDTA (pH 7.4), centrifuged again, resuspended in the same buffer, flash-frozen, and stored at -80°C until I2-imidazoline binding assays. H]idazoxan for determination of specific binding to R2 adrenoceptors, I1-PBS, and I2-PBS, respectively, were performed by a modification of methods previously described. 43, 44 Membranes were slowly thawed and diluted to a concentration of 0.4 mg of protein/mL for renal and cerebral cortex and 0.7 mg of protein/mL for calf's bulbis. Assays were conducted in a total volume of 525 µL in polypropylene tubes, and each tube contained 500 µL of membrane suspension, 20 µL of radioligand, and 5 µL of drug. Incubation was initiated by the addition of membrane and was carried out for 45 min at 25°C. Nonspecific binding was defined in the presence of yohimbine (10 µM Binding results were analyzed by linear regression, and the curves were obtained with Graph PAD program (Institute for Scientific Information, Philadelphia, PA). K i was calculated with the Cheng-Prusoff equation.
Analytical Methods. Plasma glucose was determined using a glucose analyzer (Beckman Inc., Fullerton, CA). Plasma immunoreactive insulin (IRI) concentration was determined with a radioimmunoassay kit (CEA, Gif-sur-Yvette, France). The lower limit of the assay was 19.5 pmol/L with a coefficient of variation within and between assays of 6%.
Statistics. Results of Tables 1-3 are expressed as a mean ( SEM. The significance of differences between means was evaluated by one-way analysis of variance (ANOVA), and differences were considered significant at p < 0.05.
Partition Coefficients. Log P of bases was calculated according to Rekker's method 40 and from Hansch's data bank. 41 f (1,2,4 -trisubstituted-piperazinyl) ) log P(piperazine) -(2f(H neg) + f(H)) ) -1.50 -1.124 ) -2.624. f(2-substitutedimidazolinyl) ) log P(tolazoline or 2-benzylimidazoline) -f(benzyl) ) 2.65 -2.359 ) +0.291. Controlled via another way: f(2-imidazolinyl) ) f(2-imidazolyl) + 2f(H) ) -0.080 + 0.364 ) +0.284 (|∆| ) 0.007). f(1,4-disubstituted-2-(4′,5′-dihydro-1′H-imidazolyl-2′-yl)piperazine) ) -2.333.
The hydrophobic fragmental constants of the 1,4-substituents of piperazine were added to this last value. manuscript preparation. This work was supported in part by the Belgian Programme on 
